1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under …
Over the last 12 months, insiders at 180 Life Sciences Corp. have bought $4,700 and sold $4,700 worth of 180 Life Sciences Corp. stock.
On average, over the past 5 years, insiders at 180 Life Sciences Corp. have bought $101,930 and sold $56,573 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Woody James N. (Chief Executive Officer) — $4,700.
The last purchase of 25,000 shares for transaction amount of $4,700 was made by Woody James N. (Chief Executive Officer) on 2023‑12‑15.
2023-12-15 | Sale | director | 25,000 0.3408% | $0.19 | $4,700 | -39.50% | ||
2023-12-15 | Chief Executive Officer | 25,000 0.3408% | $0.19 | $4,700 | -39.50% | |||
2023-06-01 | director | 18,000 0.4949% | $1.23 | $22,068 | -75.14% | |||
2023-05-31 | director | 10,000 0.2685% | $1.15 | $11,470 | -73.87% | |||
2023-05-19 | director | 5,000 0.1238% | $1.16 | $5,800 | -71.16% | |||
2023-05-18 | Chief Executive Officer | 40,000 1.0572% | $1.03 | $41,200 | -65.28% | |||
2023-05-18 | director | 10,000 0.2694% | $1.05 | $10,500 | -65.28% | |||
2023-05-18 | director | 7,082.02 0.1926% | $1.06 | $7,507 | -65.28% | |||
2023-05-18 | CFO | 5,162.08 0.1338% | $1.01 | $5,214 | -65.28% | |||
2021-12-16 | COO / Chief Business Officer | 8,000 23.6901% | $3.98 | $31,840 | -69.82% | |||
2021-12-10 | Interim CFO | 3,800 10.646% | $3.87 | $14,706 | -69.53% | |||
2021-12-10 | COO / Chief Business Officer | 4,500 12.7049% | $3.90 | $17,550 | -69.53% | |||
2021-12-10 | director | 1,000 2.9681% | $4.10 | $4,100 | -69.53% | |||
2021-12-09 | director | 5,000 15.7263% | $4.27 | $21,350 | -68.88% | |||
2021-12-09 | Chief Executive Officer | 12,500 39.3157% | $4.27 | $53,375 | -68.88% | |||
2021-12-09 | director | 25,000 76.0533% | $4.13 | $103,250 | -68.88% | |||
2021-12-09 | director | 12,500 36.6824% | $3.98 | $49,800 | -68.88% | |||
2020-12-17 | Sale | 10 percent owner | 16,506 65.4229% | $2.48 | $40,880 | +109.89% | ||
2020-12-15 | Sale | 10 percent owner | 17,877 81.3034% | $2.40 | $42,905 | +148.54% | ||
2020-12-14 | Sale | 10 percent owner | 10,000 45.4755% | $2.45 | $24,500 | +143.44% |
Woody James N. | Chief Executive Officer | 66888 3.3833% | $2.26 | 4 | 0 | +12.83% |
STEINMAN LAWRENCE | director | 48129 2.4344% | $2.26 | 2 | 0 | <0.0001% |
McGovern Jr. Donald A. | director | 30099 1.5225% | $2.26 | 4 | 0 | <0.0001% |
Vu Quan Anh | COO / Chief Business Officer | 20500 1.0369% | $2.26 | 2 | 0 | |
Marrone Pamela G | director | 12469 0.6307% | $2.26 | 2 | 0 | <0.0001% |